Wire · operational-macro
Cathie Wood's ARK Invest Rotates $22 Million in Biotech, Extends Intellia Buying Streak to ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 6 October 2026 · Fusion42 review
ARK Invest rotated $22 million within biotech, selling Twist Bioscience amid gains while increasing stakes in Recursion Pharmaceuticals, Intellia Therapeutics, and Veracyte, signalling a shift toward near-term clinical and diagnostic milestones in genomics. Intellia's ongoing FDA priority review for an in-vivo CRISPR therapy highlights a key regulatory event influencing ARK's accumulation strategy.
This Wire brief tracks ARK Invest, and It sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a shift in biotech capital flows favouring companies closer to regulatory approvals like Intellia. Rebalancing your exposure to gene editing and AI-driven drug discovery now can align you with investors targeting near-term catalysts.
◆ Mentioned in this story
◆ Coverage
1 source · 6 Oct 2026
◆ Related on Wire
◆ Topics